ASPIRA PATHLAB & DIAGNOSTICS | TRANSGENE BI | ASPIRA PATHLAB & DIAGNOSTICS / TRANSGENE BI |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | -29.0 | - | View Chart |
P/BV | x | 2.6 | 4.7 | 53.8% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS TRANSGENE BI |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
TRANSGENE BI Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / TRANSGENE BI |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 4 | 1,700.7% | |
Low | Rs | 26 | 2 | 1,125.0% | |
Sales per share (Unadj.) | Rs | 14.0 | 0 | 193,551.9% | |
Earnings per share (Unadj.) | Rs | -0.1 | -0.8 | 10.9% | |
Cash flow per share (Unadj.) | Rs | 1.5 | -0.1 | -1,040.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 1.5 | 825.8% | |
Shares outstanding (eoy) | m | 10.29 | 75.77 | 13.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 460.8 | 0.8% | |
Avg P/E ratio | x | -583.7 | -4.2 | 13,836.7% | |
P/CF ratio (eoy) | x | 34.6 | -23.9 | -144.5% | |
Price / Book Value ratio | x | 4.1 | 2.2 | 182.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 253 | 204.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 3 | 1,839.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 1 | 26,285.5% | |
Other income | Rs m | 3 | 2 | 183.4% | |
Total revenues | Rs m | 148 | 2 | 6,425.2% | |
Gross profit | Rs m | 16 | -6 | -261.1% | |
Depreciation | Rs m | 16 | 50 | 32.0% | |
Interest | Rs m | 4 | 6 | 66.8% | |
Profit before tax | Rs m | -1 | -60 | 1.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 0 | - | |
Profit after tax | Rs m | -1 | -60 | 1.5% | |
Gross profit margin | % | 11.0 | -1,109.7 | -1.0% | |
Effective tax rate | % | 0 | 0 | - | |
Net profit margin | % | -0.6 | -10,924.7 | 0.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 9 | 655.0% | |
Current liabilities | Rs m | 16 | 105 | 15.1% | |
Net working cap to sales | % | 29.5 | -17,405.0 | -0.2% | |
Current ratio | x | 3.7 | 0.1 | 4,325.7% | |
Inventory Days | Days | 88 | 883,618 | 0.0% | |
Debtors Days | Days | 590 | 56,050,727 | 0.0% | |
Net fixed assets | Rs m | 115 | 1,415 | 8.1% | |
Share capital | Rs m | 103 | 758 | 13.6% | |
"Free" reserves | Rs m | 25 | -644 | -3.8% | |
Net worth | Rs m | 128 | 114 | 112.1% | |
Long term debt | Rs m | 10 | 50 | 19.4% | |
Total assets | Rs m | 173 | 1,424 | 12.2% | |
Interest coverage | x | 0.8 | -8.6 | -9.1% | |
Debt to equity ratio | x | 0.1 | 0.4 | 17.3% | |
Sales to assets ratio | x | 0.8 | 0 | 215,773.5% | |
Return on assets | % | 1.9 | -3.8 | -50.1% | |
Return on equity | % | -0.7 | -52.9 | 1.3% | |
Return on capital | % | 2.4 | -33.0 | -7.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 0 | - | |
From Investments | Rs m | 2 | NA | -1,325.0% | |
From Financial Activity | Rs m | -9 | NA | - | |
Net Cashflow | Rs m | -8 | 0 | 6,566.7% |
Indian Promoters | % | 18.7 | 23.6 | 79.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 76.4 | 106.4% | |
Shareholders | 1,512 | 12,426 | 12.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | TRANSGENE BI | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | -5.82% | 0.45% |
1-Month | -8.93% | -15.14% | 2.55% |
1-Year | -3.33% | 188.26% | 56.14% |
3-Year CAGR | 1.86% | 13.97% | 15.22% |
5-Year CAGR | -1.91% | 8.99% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the TRANSGENE BI share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of TRANSGENE BI the stake stands at 23.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of TRANSGENE BI.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
TRANSGENE BI paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of TRANSGENE BI.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.